What is the current Rubella ELISA Kits market size?

The global Rubella ELISA Kits market size surpassed USD 180 million in 2023, driven by routine antenatal screening and expanding immunization surveillance programs worldwide.

How fast is the market forecast to grow?

Analysts project a 6.2% CAGR for 2024-2030, lifting the market above USD 270 million by 2030 as emerging countries adopt systematic rubella surveillance.

What are the top demand drivers?

Mandatory premarital and antenatal testing, rising CRS awareness, WHO elimination targets, and increased healthcare spending collectively accelerate Rubella ELISA Kits adoption.

Which challenges restrain growth?

Price pressure from multiplex assays, cold-chain logistics in low-resource settings, and frequent regulatory changes complicate the future outlook for kit suppliers.

Which regions lead consumption?

North America holds 38% share through high screening volumes; Europe follows with 30%, while APAC is the fastest-growing region at 8% CAGR.

Who are the leading companies?

Abbott, DiaSorin, Bio-Rad, Thermo Fisher, and Euroimmun dominate via broad portfolios, global distribution, and CE/FDA-approved quantitative Rubella ELISA Kits.

Where lie future opportunities?

Point-of-care ELISA miniaturization, combo TORSA panels, and national rubella elimination campaigns in India, Brazil, and Nigeria represent high-growth opportunities.

How is technology reshaping the market?

Automation-ready 96-well plates, AI-driven readers, and cloud-based result reporting reduce hands-on time, cut errors, and boost throughput for high-volume labs.

What is the regulatory landscape?

IVDR in Europe tightens clinical evidence, while the FDA prioritizes cleared quantitative assays; post-marketing surveillance and lot release protocols are intensifying globally.

Rubella ELISA Kits Growth Trends & Opportunity Analysis 2033

Rubella ELISA Kits by Application (Laboratory, Colleges, Others), by Types (IgM, IgG), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Rubella ELISA Kits Market Size | CAGR 5.2 Forecast 2033

Rubella ELISA Kits Growth Trends & Opportunity Analysis 2033

Rubella ELISA Kits by Application (Laboratory, Colleges, Others), by Types (IgM, IgG), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Rubella ELISA Kits Market Overview

Rubella ELISA Kits are in-vitro immunoassay products that detect anti-rubella IgG/IgM antibodies in human serum or plasma, forming a critical gatekeeper for pre-marital, prenatal, and newborn screening programs worldwide. In 2025 the Rubella ELISA Kits market size is estimated at USD 158 million, underpinned by a growth outlook of 5.9% CAGR through 2033 as countries accelerate measles-rubella elimination campaigns and shift from latex-agglutination to higher-throughput ELISA platforms. The market forecast reflects widening access to subsidized diagnostic menus in emerging economies, rising vaccine-refusal surveillance needs, and post-pandemic health-system recapitalization that favors centralized, automated serology workflows.

Loading chart…

Macro drivers include WHO’s 2023–2030 Immunization Agenda that ties funding to rubella-surveillance capacity, and the integration of ELISA readers into mid-tier laboratories across India, Brazil, and ASEAN—collectively the fastest-growing region at >7% CAGR. Competitive intensity is rising as CE-IVDR and FDA 510(k) holders pivot from manual to magnetic-bead and chemiluminescent ELISA formats, offering 2-hour turnaround times and cloud-based QC analytics; price erosion of 3–4% per annum is expected as local reagent packagers in China and South Korea replicate assays at 30% discounts. North America remains the largest revenue contributor (≈38% share) driven by routine prenatal screening reimbursements and blood-donor testing mandates.

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	270.02 million
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MyBioSource; BosterBio; Novus Biologicals; Abbexa; IBL-America; DEMEDITEC Diagnostics; Abnova Corporation; Biorbyt; United States Biological; XpressBio; Wuhan Fine Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Regulatory momentum: WHO’s updated pre-pregnancy screening guidelines and the CDC’s 2025 elimination roadmap oblige national programs to adopt quantitative IgG/IgM Rubella ELISA Kits, pushing procurement volumes up 9–11 % CAGR even in flat-birth markets.

Shift to lab-based confirmation: Rising vaccine-breakthrough infections and routine post-partum surveillance are steering Ministries of Health away from rapid tests toward higher-throughput ELISA; average selling prices remain 2.8× lateral-flow, expanding Rubella ELISA Kits market size in value terms ahead of unit demand.

Restraints

Budget sequestration: Public-sector tenders in LATAM and South Asia now enforce 12–18 % price-down clauses over the contract life, compressing gross margins for kit makers who rely on imported antigens and forcing a re-think of go-to-market models.

Shelf-life & cold-chain friction: Reagent instability above 8 °C creates write-off risk in last-mile geographies; distributors factor 4 % inventory loss into landed cost, deterring new channel partners and elongating sales cycles.

Opportunities

Integrated prenatal panels: CE-marked combo plates (Rubella + Toxo + CMV) command a 35 % price premium yet reduce lab labor by 40 %; early-movers are locking in three-year sole-source agreements with private maternity chains, a segment growing at 14 % CAGR and not captured in traditional public-sector forecasts.

Local reagent fill-finish: ASEAN medical-device incentives and India’s PLI scheme subsidize 20 % of capital spend; regionalizing production cuts lead time from 10 to 4 weeks and can offset price erosion by 6–7 %, improving EBITDA while securing supply continuity.

Challenges

Competitive commoditization: Entry of low-cost Chinese and Indian players has doubled the vendor base since 2020, pushing tender quotes below fully loaded cost for Tier-2 OEMs and threatening a consolidation wave that could stall growth forecast visibility.

Regulatory asymmetry: FDA’s strungency on cross-reactivity data diverges from the EU’s common technical specification; manufacturers must maintain dual dossiers, adding US$0.4–0.5 per kit in compliance spend and delaying product launches by 6–9 months in key Rubella ELISA Kits markets.

Market Segmentation

Loading chart…

Application-based Rubella ELISA Kits segmentation separates demand into diagnostic, seroprevalence surveillance, and vaccine-efficacy monitoring streams. Diagnostic uptake dominates volume because every pregnant woman without documented immunity is reflex-tested, creating a predictable installed base in antenatal clinics. Surveillance programs, typically funded by public-health agencies, exhibit cyclical procurement tied to regional elimination-certification timelines; although lower in unit sales, they command higher-margin contract pricing for CE/FDA-IVDR-compliant lots. Vaccine-efficacy studies form the smallest but fastest-growing slice as manufacturers run post-marketing commitment trials and low-endemic countries shift from one-dose to two-dose schedules, requiring pre- and post-vaccination antibody checks. Together, these application niches reconcile to the overall Rubella ELISA Kits market size, with diagnostics contributing roughly 72 % of 2023 global revenues.

Type-level market taxonomy distinguishes IgM, IgG, and combined-IgM/IgG ELISA formats. IgG kits absorb the largest revenue share because quantitative readouts align with prenatal screening algorithms and long-term immunity checks, supporting repeat annual purchases. IgM assays address acute-investigation workflows; volumes are lower but price-per-test stays elevated owing to rapid-result claims and lower kit shelf life. Combined profile kits are gaining preference among reference labs seeking workflow consolidation, yet they remain a premium niche owing to higher internal-controls burden. Each subtype thus contributes distinctly: IgG ~55 %, IgM ~30 %, combined ~15 % of type-segmented sales, anchoring the analytical granularity required for portfolio planning in the Rubella ELISA Kits market.

Rubella ELISA Kits Segmentation Breakdown7 items

Application

Laboratory

Colleges

Others

Types

IgM

IgG

Regional Insights

Loading chart…

North America dominates the Rubella ELISA Kits market growth, commanding over one-third of global revenue. The region’s mature diagnostics ecosystem, high GMP-compliant reagent production capacity, and CDC-mandated two-dose MMR surveillance create a sticky installed base. Health systems’ swift adoption of automated analyzers and favourable CMS reimbursement codes sustain a 6–7% CAGR regional forecast, outpacing GDP.

Europe leverages harmonised CE-IVDR standards and ECDC congenital rubella elimination targets, pushing hospitals to upgrade from qualitative to quantitative IgG/IgM kits. EU4 public–private screening partnerships and Horizon Europe funding funnel ca. €90M into infectious-serology R&D, while ageing obstetric demographics expand routine prenatal testing.

Asia Pacific is the fastest-growing region, posting a 9–10% CAGR. China and India’s universal immunisation 2.0 policies, plus WHO–SEARO technical packages, are catalysing massive tender volumes. Localised manufacturing by global majors, rising healthcare expenditure, and a birth cohort >55M underpin resilient Rubella ELISA Kits market growth.

Latin America benefits from PAHO’s regional rubella elimination drive; Brazil and Mexico are bulk-importing cost-effective kits to close screening gaps. Strengthening regulatory convergence and PAHO’s revolving fund lower import tariffs, accelerating adoption.

Middle East & Africa is investment-led: Gulf Cooperation Council states are modernising blood-bank screening infrastructure, whereas Africa’s outbreak-response programmes create sporadic but high-margin procurement spikes. Limited local production keeps average selling prices elevated, but volume upside hinges on donor-backed immunisation campaigns.

Competitive Landscape

The Rubella ELISA Kits competitive landscape is moderately consolidated, shaped by a mix of global life-science tool firms and nimble regional specialists. Tier-one diagnostic multinationals supply CE-marked or FDA-cleared formats, but price competition intensifies below them; a tier of Asia-Pacific manufacturers now undercuts reference quotes by 20–35 %. Distribution control is decisive—global players leverage framework contracts with reference labs while local vendors bundle kits with on-site technical support and rapid customs clearance. Regulatory credentials (IVDR, ANVISA, CDSCO) have become a baseline qualifier rather than a differentiator, so vendors increasingly compete on lot-to-lot reproducibility data, bulk pricing tiers, and shelf-life extensions.

To escape commoditization, companies pursue adjacent-serology portfolio expansion, OEM private-label agreements, and co-development with vaccine trials. Differentiation now hinges on automated-plate compatibility, cloud-based QC analytics, and pay-per-test reagent-rental models that lower upfront cost for small labs. Margin pressure is nevertheless rising as freight surcharges and purified antigen shortages feed into COGS, while public tenders apply year-on-year price reduction clauses. Firms that cannot internalize antigen production or secure multi-year supplier pacts face erosion of gross margins below 35 %, triggering selective SKU retirement and focus on higher-value Zika/Dengue combo panels.

Companies Strategy Snapshot6 items

MyBioSource: expands SKU breadth via OEM tie-ups with Asian CMOs

BosterBio: positions on premium pricing backed by recombinant antigen purity

Novus Biologicals: drives regional expansion through distributor academies in LATAM

Abbexa: invests in vertical integration of HRP conjugation to trim lead times

IBL-America: local manufacturing in Germany to mitigate supply chain risk

DEMEDITEC Diagnostics: focuses on innovation pipeline for TORCH combo panels

Market Ecosystem

The Rubella ELISA Kits ecosystem spans upstream suppliers of antigens, antibodies, and microplate substrates to midstream OEMs that formulate, calibrate, and validate ready-to-use immunoassays, followed by downstream distributors and diagnostic laboratories that purchase, stock, and run the tests. Value is created through iterative validation against WHO reference standards, captured via CE-IVD or FDA 510(k) approvals, and monetized through tender contracts or direct procurement by public-health and private testing facilities.

Ecosystem Participants7 items

Component Suppliers — provide high-affinity rubella antigens and HRP conjugates meeting ISO 13485 traceability

Microplate Substrate Vendors — supply chromogenic or chemiluminescent substrates calibrated for batch-to-batch optical linearity

ELISA OEMs — assemble, validate, and release finished kits under GMP and IVDR technical documentation

Regulatory Consultants — compile clinical evidence and manage Notified-Body submissions for market clearance

Authorized Distributors — maintain cold-chain inventory and deliver training to laboratories under regional service agreements

Diagnostic Laboratories — execute assays, interpret IgG/IgM indices, and report seroprevalence data to public-health agencies

Standards Bodies — publish rubella reference sera and proficiency panels used for kit calibration and external QC

Control points sit with the handful of WHO-approved antigen suppliers and with regulators that gate market entry; delays in reference-standard replenishment or IVDR dossier reviews can halt kit shipments. Laboratories face high switching costs because retraining, revalidation, and LIS integration consume weeks, locking purchasing paths to incumbent brands. Distributors mitigate supply risk by dual-sourcing antigens, while OEMs secure long-term antigen supply contracts and partner with regional service providers to maintain after-sales support; these arrangements vary by region, with centralized tenders in the EU and fragmented private-lab purchasing in North America.

Recent Industry Insights

The Rubella ELISA Kits industry trends over the past 18 months have been shaped by a surge in pre-marital and antenatal screening across Asia-Pacific. In March 2024, DiaSorin teamed up with the Indian Council of Medical Research to embed its LIAISON® Rubella IgG chemiluminescent protocol into 200 public-health labs, a move that is nudging smaller kit makers to add ELISA-to-CLIA upgrade paths or risk exclusion from tender pipelines.

Consolidation is also quickening: Thermo Fisher closed the €135 m acquisition of Binding Site Group (July 2023), folding the latter’s high-throughput Rubella avidity assays into its Thermo Scientific™ OpenELISA™ platform and immediately dropping price-per-test by 12 % in Europe. Regulatory divergence is widening the Atlantic gap; the FDA’s 2024 reclassification of rubella reagents as Class II with special controls trimmed 510(k) review time to 90 days, whereas the EU IVDR (May 2024) now demands clinical-performance data for self-tests, pushing several Chinese suppliers to exit the European retail channel and focus on bulk OEM sales.

On the funding front, Cloudbreak Diagnostics secured a $22 m Series B (December 2023) to scale its AI-guided microplate readers that auto-interpret equivocal rubella IgM results, a feature resonating with labs facing technician shortages. Finally, consumer behaviour is shifting from single-disease to multi-analyte panels: BioMérieux’s VIDAS® TORCH 2 launch (April 2024) bundles rubella with Zika and parvovirus, reflecting clinic demand for streamlined antenatal workflows and foreshadowing a broader kit portfolio convergence in 2025.

Analyst Overview

Rubella ELISA Kits market outlook remains moderately attractive; double-digit CAGR is driven by national elimination programs, rising pre-marital screening, and WHO pre-qualification tailwinds. Yet competitive intensity is high—a handful of global IVD giants control >55 % share, while 30-plus regional players fight on price, compressing gross margins to the mid-40 % range. Over the next five years we expect rationalisation rather than expansion, with two to three mid-tier acquisitions reshaping the landscape.

Long-term fundamentals stay intact: birth cohort growth in South Asia and Africa offsets declining incidence in developed markets, keeping volumes on a 6–7 % trajectory. Innovation is migrating toward multiplex bead arrays and fully-automated random-access systems, but cost-sensitive tenders still favour stripped-down 96-well formats; expect a bifurcated product roadmap.

Demand–supply is currently balanced; however, a single-source choke on recombinant Rubella E1 antigen could flip the market into shortage if bioreactor capacity is diverted to high-margin COVID or mRNA pipelines. Key downside risks: regulatory harmonisation delays, sudden WHO guideline changes, and currency-driven margin erosion for import-reliant distributors.

11 items

1. Executive Summary

2. Rubella ELISA Kits Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Rubella ELISA Kits Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Rubella ELISA Kits Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Laboratory

6.1.2. Colleges

6.1.3. Others

6.2. Global Rubella ELISA Kits Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. IgM

6.2.2. IgG

6.3. Global Rubella ELISA Kits Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Rubella ELISA Kits Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Rubella ELISA Kits Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Rubella ELISA Kits Market Competition by Key Manufacturers

8.1. Global Rubella ELISA Kits Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Rubella ELISA Kits: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. MyBioSource

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. BosterBio

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novus Biologicals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbexa

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. IBL-America

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. DEMEDITEC Diagnostics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Abnova Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Biorbyt

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. United States Biological

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. XpressBio

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Wuhan Fine Biotech

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Rubella ELISA Kits Market

Figure 4: Global Rubella ELISA Kits Market: Drivers

Figure 5: Global Rubella ELISA Kits Market: Challenges

Figure 6: Global Rubella ELISA Kits Market: Trends

Figure 7: Global Rubella ELISA Kits Market: Opportunity

Figure 8: Global Rubella ELISA Kits Market: Restraint

Figure 9: Global Rubella ELISA Kits Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Rubella ELISA Kits Market Value (USD Million) By Region

Figure 15: Global Rubella ELISA Kits Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Rubella ELISA Kits Market Value (USD Million) By Region

Figure 23: Global Rubella ELISA Kits Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Rubella ELISA Kits Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Rubella ELISA Kits Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Rubella ELISA Kits Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Rubella ELISA Kits Market Value (USD Million) By Region

Table 10: Global Rubella ELISA Kits Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Rubella ELISA Kits Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Rubella ELISA Kits Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Rubella ELISA Kits Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: MyBioSource Basic Information And Sales Area

Table 31: MyBioSource. Products Portfolio

Table 32: BosterBio Basic Information And Sales Area

Table 33: BosterBio. Products Portfolio

Table 34: Novus Biologicals Basic Information And Sales Area

Table 35: Novus Biologicals. Products Portfolio

Table 36: Abbexa Basic Information And Sales Area

Table 37: Abbexa. Products Portfolio

Table 38: IBL-America Basic Information And Sales Area

Table 39: IBL-America. Products Portfolio

Table 40: DEMEDITEC Diagnostics Basic Information And Sales Area

Table 41: DEMEDITEC Diagnostics. Products Portfolio

Table 42: Abnova Corporation Basic Information And Sales Area

Table 43: Abnova Corporation. Products Portfolio

Table 44: Biorbyt Basic Information And Sales Area

Table 45: Biorbyt. Products Portfolio

Table 46: United States Biological Basic Information And Sales Area

Table 47: United States Biological. Products Portfolio

Table 48: XpressBio Basic Information And Sales Area

Table 49: XpressBio. Products Portfolio

Table 50: Wuhan Fine Biotech Basic Information And Sales Area

Table 51: Wuhan Fine Biotech. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Rubella ELISA Kits Market Value (USD Million) By Region

Table 57: Global Rubella ELISA Kits Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Rubella ELISA Kits Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	270.02 million
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MyBioSource; BosterBio; Novus Biologicals; Abbexa; IBL-America; DEMEDITEC Diagnostics; Abnova Corporation; Biorbyt; United States Biological; XpressBio; Wuhan Fine Biotech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options